Resumen de New Integrase Strand Transfer Inhibitor Approved To Treat HIV-1

Diane S. Aschenbrenner

• * A new drug, Dolutegravir (Tivicay), has been approved to treat HIV-1 infection in both treatment-naïve patients and those who have received prior therapy against HIV infection.

  * Possible serious adverse effects of the drug include hypersensitivity and abnormal liver function if the patient is coinfected with hepatitis B or hepatitis C.